Cyteir Therapeutics, Inc.
CYT · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1,375 | $479 | $351 | $13 |
| Gross Profit | -$1,375 | -$479 | -$351 | -$5 |
| % Margin | – | – | – | -58.6% |
| R&D Expenses | $34,624 | $30,959 | $16,765 | $12,768 |
| G&A Expenses | $13,546 | $11,300 | $4,178 | $3,345 |
| SG&A Expenses | $13,546 | $11,300 | $4,178 | $3,345 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2,109 | $133 | $120 | -$8 |
| Operating Expenses | $48,170 | $42,259 | $20,943 | $16,105 |
| Operating Income | -$48,170 | -$42,259 | -$20,943 | -$16,105 |
| % Margin | – | – | – | -201,312.5% |
| Other Income/Exp. Net | $2,109 | $133 | $120 | $1,061 |
| Pre-Tax Income | -$46,061 | -$42,126 | -$20,823 | -$15,044 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$43,952 | -$41,647 | -$20,823 | -$15,044 |
| % Margin | – | – | – | -188,050% |
| EPS | -1.25 | -1.18 | -0.87 | -0.77 |
| % Growth | -5.9% | -35.6% | -13% | – |
| EPS Diluted | -1.25 | -1.18 | -0.87 | -0.77 |
| Weighted Avg Shares Out | 35,273 | 35,189 | 23,890 | 19,434 |
| Weighted Avg Shares Out Dil | 35,273 | 35,189 | 23,890 | 19,434 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $133 | $120 | $246 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $668 | $479 | $351 | $215 |
| EBITDA | -$46,061 | -$41,780 | -$20,592 | -$15,890 |
| % Margin | – | – | – | -198,625% |